Ex-GSK CEO, R&D chief An­drew Wit­ty and Mon­cef Slaoui are jump­ing in­to the biotech VC game

Top phar­ma ex­ecs at the mar­quee com­pa­nies don’t re­al­ly re­tire. Some segue quite nat­u­ral­ly in­to ven­ture cap­i­tal, where their con­tacts and heavy­weight in­dus­try rep­u­ta­tions can fa­cil­i­tate the growth of lit­tle biotech com­pa­nies at a time the VC crowd is en­joy­ing a pro­longed and pop­u­lar boom.

This morn­ing two of the biggest names that once dom­i­nat­ed GSK for a decade, the new­ly re­tired CEO An­drew Wit­ty and long­time R&D chief Mon­cef Slaoui, mapped out their plans to jump in­to the biotech ven­ture cap­i­tal game. Sir An­drew has signed on as a part­ner at Durham, NC-based Hat­teras Ven­ture Part­ners, while Slaoui has joined the Eu­ro­pean team at Medicxi.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Principal

Alexandria Real Estate Equities

Cambridge, MA, USA